News

CGeneTech and Medicilon PROTAC project reached a strategic cooperation

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2020-12-04
  • Views:0

(Summary description)Recently, CGeneTech (Suzhou, China) Co., Ltd. and Medicilon Biomedical Co., Ltd. have successfully reached a strategic cooperation on PROTAC project. In this collaboration, CGeneTech will use the proven technology provided by Medicilon with PROTAC technology as the core technology. Unlike the traditional drug development concept of inhibiting the activity or function of disease-causing proteins, PROTAC (proteolysis-targeting chimera) therapy uses the natural mechanism of proteins in cells to degrade disease-causing target proteins in order to intervene or treat diseases.

CGeneTech and Medicilon PROTAC project reached a strategic cooperation

(Summary description)Recently, CGeneTech (Suzhou, China) Co., Ltd. and Medicilon Biomedical Co., Ltd. have successfully reached a strategic cooperation on PROTAC project. In this collaboration, CGeneTech will use the proven technology provided by Medicilon with PROTAC technology as the core technology. Unlike the traditional drug development concept of inhibiting the activity or function of disease-causing proteins, PROTAC (proteolysis-targeting chimera) therapy uses the natural mechanism of proteins in cells to degrade disease-causing target proteins in order to intervene or treat diseases.

  • Categories:Company News
  • Author:
  • Origin:
  • Time of issue:2020-12-04
  • Views:0

Recently, CGeneTech (Suzhou, China) Co., Ltd. and Medicilon Biomedical Co., Ltd. have successfully reached a strategic cooperation on PROTAC project. In this collaboration, CGeneTech will use the proven technology provided by Medicilon with PROTAC technology as the core technology. Unlike the traditional drug development concept of inhibiting the activity or function of disease-causing proteins, PROTAC (proteolysis-targeting chimera) therapy uses the natural mechanism of proteins in cells to degrade disease-causing target proteins in order to intervene or treat diseases.

Dr. Qiang Yu and Dr. Feng Ren complete the contract online

 

Medicilon Chemistry has summarized the current popular target protein ligands and established an extensive library of highly affinity small molecules and small molecule fragments of popular target proteins compounds (TPSM), an extensive linker system of E3 ligase highly affinity small molecules and small molecule fragments (E3SM) and bifunctional linkers (BF-Linker) with a wide diversity of On this basis, we have successfully constructed a series of PROTAC protein degradation targeting chimeras, which greatly enhance the drug discovery process using PROTAC technology.

Medixi has also established and perfected the PROTAC biological screening and testing platform. The Biology Department has mature PROTAC functional assay and validation technology, and has established a high-throughput PROTAC screening platform using fusion protein expression and BiFC (Dual Fluorescence Molecular Complementation) technology to screen PROTAC small molecules for targeted degradation of disease-causing proteins.

At the end of the meeting, Dr. Qiang Yu, CEO of CGeneTech, wrote a poem to express his hopes and wishes for the future collaboration project.

The peak is like an axe.

Mountains open cliffs stand.

There is no time for leisurely clouds RaO,

Climbing to the top with the sky T.

The dream of the prosperous world is mA.

Tongcheng Medi C!

 

About CGeneTech

CGeneTech (Suzhou, China) Co., Ltd. is a high-tech enterprise dedicated to the research, development, production and sales of small molecule innovative drugs. Since its establishment, the company has applied for several invention patents and has been granted 2 patents. Among them, Shengliptin, a new class 1.1 hypoglycemic drug, has been successfully selected for the National 12th Five-Year Plan and 13th Five-Year Plan "Major New Drug Creation", and has been included in the track of key support for innovative drugs at the national level. Preclinical studies have shown that the key technical parameters and long-term benefits of Shengliptin are significantly better than those of its global counterpart, selegiline, and clinical approval was obtained from the State Drug Administration in 2017. Centigliptin's flash release formulation technology was also awarded the title of Suzhou Engineering Center, on which the special formulation new drug project represented by Asenapine was developed, and more new class 2 improved drugs will be developed on this platform in the future.

About Medicilon

Founded in 2004 and headquartered in Shanghai, Medicilon (stock code: 688202) is dedicated to providing a full range of preclinical new drug research services to pharmaceutical companies, research institutions and researchers worldwide. Medici's one-stop integrated services help clients accelerate their drug discovery process with strong project management and more efficient and cost-effective R&D services, covering the entire preclinical drug discovery process, including drug discovery, pharmacology and preclinical studies. Medixi has grown with domestic and international quality clients, providing new drug development services to more than 700 clients worldwide. Medixi will continue to contribute to human health with a global vision and focus on innovation in China!

The

The world's first SGLT-2/DPP-4 dual target inhibitor with complementary advantages has been approved for clinical use

Recently, Shengshi Taike's Class 1 innovative drug SGLT-2/DPP-4 dual target inhibitor CGT-2201 has been granted implicit permission for clinical trials by the National Drug Administration. CGT-2201, which targets SGLT-2 and DPP-4, two important targets related to glucose metabolism, can be better used for the treatment of diabetes and its derivatives, including diabetes nephropathy and non-alcoholic fatty liver disease. In 2021, the number of diabetes patients in China will reach 141 million, ranking first in the world. Among the numerous patients with diabetes in China, 20-40% may suffer from complications of diabetes nephropathy. Among the existing hypoglycemic drugs, only sodium glucose cotransporter 2 (SGLT-2) inhibitor has significant renal protection effect in clinical verification, but its inherent reproductive and urinary system infection risks limit its use. Based on SGLT-2 inhibitors and combined with the characteristics of dipeptidyl peptidase 4 (DPP-4) inhibitors, we design and develop a drug that can improve blood sugar, reduce side effects of urinary and reproductive system infections, is not limited by renal function, and has kidney benefits. It is expected to fill the market gap and meet the needs of patients. Based on this market background and target characteristics, Shengshi Taike utilizes its own small molecule chimera drug technology platform to develop multi head multifunctional new drug products with synergistic mechanisms, with CGT-2201 being one of its representative works. It fuses the respective mechanism characteristics of SGLT-2 and DPP-4. On the basis of inhibiting the activity of SGLT-2 to reduce the reabsorption of glucose in the kidney, it also slows down the inactivation of DPP-4 on GLP-1, playing a dual role mechanism to play a superposition effect; While achieving considerable hypoglycemic effect, it can reduce the side effects of existing SGLT-2 drug urinary system infection; At the same time, without kidney excretion, it can reduce the burden of the kidney and reduce the contraindication of diabetes patients with renal insufficiency. Therefore, this drug will have the advantage of better controlling blood sugar and protecting patient kidney function. Shengshi Tyco was founded in Suzhou Industrial Park in 2010. Its core team has decades of experience in the whole life cycle of international drugs, and is committed to the R&D and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a product pipeline covering multiple disease fields such as hypoglycemic, anticancer, and autoimmune diseases with an integrated drug research and development technology platform and a diversified business perspective. In the field of hypoglycemic drugs, Shenggliptin, the core product independently developed by the company, has submitted an NDA (product launch application) to the National Drug Administration and has been accepted. The results of the Phase 3 clinical trial showed that low doses can reach the predetermined trial endpoint, while the high-dose group can also demonstrate the safety of the drug well. The therapeutic effect of "half the dose" is twice as effective, making it expected to become the best hypoglycemic drug in the class. At the same time, the company has also carried out a comprehensive layout around oral drugs and derivative diseases of various targets related to diabetes. CGT-2201, which was approved for clinical use this time, is one of its pipeline matrix members.
2023-04-20

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO